PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.
Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, Sette G, Scarpa A, Konopleva M, Andreeff M, McCubrey JA, Blandino G, Todaro M, Stassi G, De Maria R, Cognetti F, Del Bufalo D, Ciuffreda L.
Milella M, et al. Among authors: de maria r, de luca t.
Sci Rep. 2017 Feb 21;7:43013. doi: 10.1038/srep43013.
Sci Rep. 2017.
PMID: 28220839
Free PMC article.